2014 ASCO AM Public - Sunday

268

Chicago, IL - The 2014 ASCO Annual Meeting - "Alan P. Venook, MD at Abstract #LBA3: ""CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC),"" Plenary Session Keyword: AM14_Alan_Venook" at the American Society of Clinical Oncology Annual Meeting here today, Sunday June 1, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Phil McCarten 2014 Technical Questions: todd@medmeetingimages.com